mRNA Cancer Vaccines: 2026 Clinical Trial Results for Melanoma, Pancreatic & Lung Cancer
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-03-28 · 10 min read
Moderna and BioNTech personalized cancer vaccines are reporting 49% recurrence reduction in melanoma. The mRNA revolution moves beyond COVID.
Personalized Cancer Vaccines Arrive
The same mRNA technology that delivered COVID-19 vaccines is now being engineered to teach the immune system to attack a patient's specific tumor mutations.
Headline Results
- Moderna mRNA-4157 + Keytruda — 49% reduction in melanoma recurrence (Phase 2b)
- BioNTech autogene cevumeran — durable immune responses in 50% of pancreatic cancer patients
- NSCLC mRNA trials — Phase 2 results expected late 2026
How Personalized Vaccines Work
- Surgeons remove the tumor
- Genomic sequencing identifies up to 34 neoantigens unique to that tumor
- A custom mRNA vaccine is manufactured in 6-8 weeks
- Patient receives 9 doses over 1 year alongside checkpoint inhibitor
Timeline to FDA Approval
Melanoma vaccine: 2026-2027 anticipated approval. Pancreatic, lung, and renal indications follow.